Objectives: In recent years, fingolimod and natalizumab - though expensive - have brought significant improvements in second-line treatment of Multiple Sclerosis (MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation criterion which exempts the manufacturer from a mandatory discount of 5% on the ex-factory price for a three-year period. Since the innovation period is soon expiring and in order to assess the affordability of this therapy for the National and Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) of fingolimod in second-line treatment of MS, enclosed an ethical assessment of justice issues.
Ruggeri, M., D'Ausilio, A., Lo Muto, R., Cottone, S., Ghezzi, A., Mecozzi, A., Sacchini, D., Mangone, M., Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis, <<VALUE IN HEALTH>>, 2014; 17 (7): 393-393. [doi:http://dx.doi.org/10.1016/j.jval.2014.08.872] [http://hdl.handle.net/10807/64978]
Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis
Ruggeri, Matteo;Sacchini, Dario;
2014
Abstract
Objectives: In recent years, fingolimod and natalizumab - though expensive - have brought significant improvements in second-line treatment of Multiple Sclerosis (MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation criterion which exempts the manufacturer from a mandatory discount of 5% on the ex-factory price for a three-year period. Since the innovation period is soon expiring and in order to assess the affordability of this therapy for the National and Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) of fingolimod in second-line treatment of MS, enclosed an ethical assessment of justice issues.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
